Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors - UTU Research Portal

A1 Refereed original research article in a scientific journal

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

Authors: Haltia UM, Hallamaa M, Tapper J, Hynninen J, Alfthan H, Kalra B, Ritvos O, Heikinheimo M, Unkila-Kallio L, Perheentupa A, Farkkila A

Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

Publication year: 2017

Journal: Gynecologic Oncology

Journal name in source: GYNECOLOGIC ONCOLOGY

Journal acronym: GYNECOL ONCOL

Volume: 144

Issue: 1

First page : 83

Last page: 89

Number of pages: 7

ISSN: 0090-8258

eISSN: 1095-6859

DOI: https://doi.org/10.1016/j.ygyno.2016.11.018

Web address : http://www.sciencedirect.com/science/article/pii/S0090825816315748

Abstract

Objective. Evaluation of circulating tumor markers in ovarian cancer is crucial for optimal patient care. The goal of this study was to verify the most accurate circulating tumor markers for the diagnosis and follow-up of adult-type granulosa cell tumors (AGCT5).Methods. The levels of circulating human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125), together with AGCT markers inhibin B and anti-Mtillerian hormone (AMH), were measured in 135 samples from AGCT patients, 37 epithelial ovarian carcinoma (EOC) patients, and 40 endometrioma (ENDO) patients. The levels were plotted with receiver operating characteristic (ROC) graphs, and the area under the curves (AUC) of the different markers were calculated and compared.Results. HE4 levels were significantly lower in AGCT5 than in EOCs (p < 0.0001). CA125 levels were above 35 IU/1 in 25% of AGCT patients and 47.5% of ENDO patients, whereas inhibin B and AMH levels were elevated only in patients with AGCT5. In the AUC comparison analyses, inhibin B alone was sufficient to differentiate AGCT from EOC. In differentiating AGCT from ENDO, inhibin B and AMH performed similarly, and the combination of inhibin B and AMH increased the accuracy compared to either marker alone (sensitivity, 100%; specificity, 93%). Among AGCT patients, inhibin B was the best marker for detecting the presence of AGCT.Conclusions. HE4 and CA125 levels were low in AGCTs, and inhibin B was the most accurate circulating biomarker in distinguishing AGCTs from EOCs and from ENDOs. Inhibin B was also the best single marker for AGCT follow-up. (C) 2016 Elsevier Inc. All rights reserved.